hVIVO plc

Equities

VENN

GB00B9275X97

Biotechnology & Medical Research

Market Closed - London S.E. Other stock markets 11:35:29 2024-04-26 am EDT			5-day change	1st Jan Change
28.25 ^GBX	-1.22%		+5.81%	+18.95%

Apr. 09	Transcript : HVIVO plc, 2023 Earnings Call, Apr 09, 2024
Apr. 09	HVIVO swings to profit and commences annual dividends as outlook rosy	AN

Investment firm European Green Transition plans listing on AIM

March 18, 2024 at 07:24 am EDT

(Alliance News) - European Green Transition Ltd on Monday said it plans to launch its initial public offering on London's AIM market in early April.

European Green Transition, which will become a PLC upon listing, intends to invest in a portfolio of green economy assets in Europe. These include critical materials projects, solar and wind farms, and rehabilitation and processing projects. It has a launch portfolio of assets, including the Olserum rare earth element project in Sweden.

The IPO will be led by Panmure Gordon (UK) Ltd as bookrunner, broker and nominated adviser.

No financial details were provided on Monday. The company's largest shareholder is Cathal Friel, a co-founder and non-executive director. Friel has 43.8% stake, including 13.7% held directly and 30.1% via Raglan Road Capital Ltd.

Friel and other members of the European Green Transition leadership team have experience with other London-listed investment vehicles, including hVIVO PLC, which is still AIM listed, and Amryt Pharma PLC.

By Tom Waite, Alliance News editor

Comments and questions to newsroom@alliancenews.com

Latest news about hVIVO plc

Transcript : HVIVO plc, 2023 Earnings Call, Apr 09, 2024	Apr. 09
HVIVO swings to profit and commences annual dividends as outlook rosy	Apr. 09	AN
HVIVO plc Provides Revenue Guidance for the Year 2024	Apr. 09	CI
Transcript : HVIVO plc, 2023 Earnings Call, Apr 09, 2024	Apr. 09
HVIVO plc Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 09	CI
European Green Transition starts trading on London's AIM market	Apr. 08	AN
Investment firm European Green Transition plans listing on AIM	Mar. 18	AN
HVIVO Chair and non-exec director sell 30.0 million shares	Feb. 14	AN
Hvivo Completes Secondary Placing	Feb. 14	MT
HVIVO directors to sell total of 14 million shares	Feb. 14	AN
Hvivo Shareholders Plan Secondary Placing to Sell 14 Million Shares	Feb. 14	MT
Transcript : HVIVO plc, Q4 2023 Sales/ Trading Statement Call, Jan 30, 2024	Jan. 30
FTSE 100 Ends on Three-Week High, Partly on Diageo Rebound	Jan. 30	DJ
HVIVO shares up after "record year" across all metrics	Jan. 30	AN
Hvivo Wins GBP6 Million Antiviral Testing Contract	Jan. 02	MT
HVIVO inks GBP6.3 million deal to test common cold treatment	Jan. 02	AN
New Year begins largely green amid slew of PMIs	Jan. 02	AN
HVIVO plc Signs £6.3 Million Human Challenge Study Model	Jan. 02	CI
Hvivo Secures GBP17 Million Contract for RSV Antiviral Drug Testing; Stock Surges	Dec. 13	MT
HVIVO signs deal to test RSV antiviral drug candidate with study model	Dec. 13	AN
HVIVO celebrates positive results for Pneumagen's Neumifil in trial	23-10-05	AN
HVIVO interim profit jumps on revenue increase; ups full-year guidance	23-09-12	AN
HVIVO raises 2023 revenue view on demand for respiratory therapy testings	23-09-12	RE
UK Stocks-Factors to watch on Sept 12	23-09-12	RE
Earnings Flash (HVO.L) HVIVO Reports H1 Revenue GBP27.3M	23-09-12	MT

Chart hVIVO plc

Duration

Period

More charts

Company Profile

hVIVO plc is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and therapeutics using human challenge clinical trials. The Group provides end-to-end early clinical development services to its large, established and growing repeat client base, which includes four of the top 10 largest global biopharma companies. The Group's fast-growing services business includes a unique portfolio of 10+ human challenge models to test a broad range of infectious and respiratory disease products, world class challenge agent manufacturing, specialist drug development and clinical consultancy services via its Venn Life Sciences brand, and a lab offering via its hLAB brand, which includes virology, immunology biomarker and molecular testing. The Group offers additional clinical field trial services such as patient recruitment and clinical trial site services. hVIVO plc runs challenge studies in London from its Whitechapel quarantine clinic, its state-of-the-art QMB clinic with its highly specialized on-site virology and immunology laboratory, and its clinic in Plumbers Row. To recruit volunteers / patients for its studies, the Company leverages its unique clinical trial recruitment capacity via its FluCamp volunteer screening facilities in London and Manchester.

Sector

Biotechnology & Medical Research

Calendar

2024-05-13 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for hVIVO plc

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.2825 GBP

Average target price

0.3607 GBP

Spread / Average Target

+27.68%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
HVIVO PLC	+18.95%	239M
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research